Directly LLy but indirectly DYAX. I believe when LLY acquired Imclone they got Ramucirumab which was discovered using Dyax's technology (they get royalty payments from LLY if drug is successful). The statistical efficacy of the drug was not as strong as strong as hoped when initial results came out last year (gastric indication). Also, last year Amgn halted trial (ph. II) of Ganitumab (pancreatic cancer) after inconclusive results. This is what I meant by general statement 'mixed results'.